Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Idera Pharmaceuticals, Inc. (IDRA)

IDRA RSS Feed
Add IDRA Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Seel
Search This Board:
Last Post: 12/18/2014 10:51:40 AM - Followers: 116 - Board type: Free - Posts Today: 2



The Company has created DNA-based compounds that in preclinical studies act as antagonists of TLR7 and TLR9, such as IMO-3100, or as antagonists of TLRs 7, 8, and 9, such as IMO-8400. The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis. It has selected IMO-8400, an antagonist of TLRs 7, 8, and 9, for development in the treatment of autoimmune diseases, with lupus as the initial disease indication. IMO-2055, a TLR9 agonist, is its lead drug candidate for the treatment of cancer. Clinical trials of IMO-2055 completed by the Company or by Merck KGaA include four Phase I clinical trials, of which two were in healthy subjects and two were in refractory cancer patients, and one Phase II clinical trial. The Phase II clinical trial was a monotherapy trial of IMO-2055 in patients with metastatic or recurrent clear cell renal cancer.


In preclinical animal models, the Company TLR7, 8, and 9 agonists have shown adjuvant activity when combined with various types of antigens. It has designed and created a new class of molecules to inhibit gene expression. These gene silencing oligonucleotides, which it refer to as GSOs, are nucleic acid-based and represent a novel approach to selectively, silence gene expression. It is actively engaged in preclinical research with its GSOs that is designed to explore their potential as research reagents and therapeutic agents. In addition to the Company’s clinical programs in autoimmune and inflammatory diseases and in cancer, it has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies, and TLR3 agonists for use as vaccine adjuvants.


IMO-2125, a synthetic DNA-based TLR9 agonist, is its lead candidate for the treatment of chronic hepatitis C virus (HCV), infection. The Company conducted two Phase I clinical trials of IMO-2125 in patients with chronic HCV infection, one in patients with HCV who had not responded to prior treatment and one in combination with ribavirin, an antiviral medication approved for use in combination with interferon-alpha in the treatment of HCV infection, in treatment-naive patients with genotype 1 chronic HCV infection. In addition to the use of TLR9 agonists in oncology applications, it selected IMO-4200 as a lead TLR7 and TLR8 agonist candidate for the treatment of hematological cancers. Its TLR9 agonists are designed to induce immune responses that could be useful in restoring immune system balance. IMO-2134 is its lead TLR9 agonist for asthma and allergies. In addition to use of TLR7, 8, and 9 agonists as vaccine adjuvants, it also has created TLR3 agonists for potential use as vaccine adjuvants.


The Company competes with Dynavax Technologies Corporation, GlaxoSmithKline plc., Pfizer, Inc., VentiRx Pharmaceuticals., Novartis, Dynavax Technologies Corporation, VaxInnate, Inc., Intercell AG, Cytos Biotechnology AG and Celldex Therapeutics, Inc.

http://www.iderapharma.com/

 


 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IDRA
Current Price
Volume:
Bid Ask Day's Range
Wiki
Option Chain for IDRA
IDRA News: Current Report Filing (8-k) 12/17/2014 08:12:20 AM
IDRA News: Statement of Changes in Beneficial Ownership (4) 12/16/2014 06:55:00 PM
IDRA News: Statement of Changes in Beneficial Ownership (4) 12/16/2014 06:37:18 PM
IDRA News: Statement of Changes in Beneficial Ownership (4) 12/15/2014 05:02:54 PM
IDRA News: Current Report Filing (8-k) 12/15/2014 04:46:47 PM
PostSubject
#718  Sticky Note Hi Seel. Let me assure you that despite ajsmith 03/09/14 01:35:35 AM
#1485   $IDRA DD Notes ~ http://www.ddnotesmaker.com/IDRA stocktrademan 12/18/14 10:51:40 AM
#1484   A good market day for IDRA to close Citrati 12/18/14 09:28:15 AM
#1483   Piper Jaffray picks for 2015 • 10:38 AM CHM_760 12/17/14 10:43:21 AM
#1482   Idera named Top Small Cap Pick for 2015 CHM_760 12/17/14 09:30:04 AM
#1481   Interesting premarket action. Citrati 12/17/14 09:07:58 AM
#1480   Key bounce to watch for tomorrow if it DITRLI 12/15/14 09:49:36 PM
#1479   Congrats on your gains. I am guessing Citrati 12/15/14 07:53:11 PM
#1478   I sold out here about a week ago, Randolph Duke 12/15/14 06:27:48 PM
#1477   This was my comment on another board. Citrati 12/15/14 04:56:13 PM
#1476   Obviously following overall market, but anybody buying on THEPK5 12/15/14 02:56:29 PM
#1475   There is our 10ema test. A nice bounce, Citrati 12/12/14 10:13:11 AM
#1474   What is going on with IDRA? Citrati 12/10/14 10:37:30 PM
#1473   Thanks a lot DD, much appreciated! binchey 12/09/14 01:59:45 PM
#1472   Congratz on IDRA so far and best of doogdilinger 12/09/14 12:56:30 PM
#1471   popped up on my unusual volume scan, should DITRLI 12/08/14 08:52:55 PM
#1470   Great news for IDRA and for us! They Seel 12/08/14 07:26:30 PM
#1469   Idera +6.3% AH after presenting IMO-8400 data CHM_760 12/08/14 07:05:54 PM
#1468   Based on the after-hours pop (currently 5.44%) my CHM_760 12/08/14 06:56:19 PM
#1467   Think we'll get a morning pop? jcseattle 12/08/14 06:51:30 PM
#1466   Awesome news. Thanks. Citrati 12/08/14 06:28:57 PM
#1465   Idera Pharmaceuticals Presents Data Supporting IMO-8400 as Novel CHM_760 12/08/14 06:21:25 PM
#1464   Very nice day, right up close to HOD. Citrati 12/08/14 04:16:11 PM
#1463   Chart looks nice, should be a good one DITRLI 12/08/14 12:57:01 AM
#1462   DLBCL trial update 04/15 (very key event in binchey 12/07/14 11:07:57 AM
#1461   Ton of potential here for sure. However, what Canoepaddler 12/07/14 09:00:32 AM
#1460   I meant "I might sell a bit at binchey 12/07/14 03:26:28 AM
#1459   IDRA is truly extraordinary pick with a huge binchey 12/07/14 03:24:24 AM
#1458   Just draw in previous higher support/resistance lines. They Citrati 12/06/14 02:08:21 AM
#1457   well did not like so much the weak close terragord7 12/05/14 10:11:50 PM
#1456   Where is this thing going?!? StockStubz 12/05/14 08:29:54 PM
#1455   Tomorrow should be interesting, on watch with others: http://ditrli.com/ditrli-t DITRLI 12/05/14 01:29:26 AM
#1454   Thank you for haring your insight... Ebuilder 12/04/14 08:24:25 PM
#1453   Back in April the stock dropped from upper stocking4ms 12/04/14 06:31:58 PM
#1452   Looks like you did well. So why Ebuilder 12/04/14 02:56:31 PM
#1451   Sold mine yesterday @4.15 and I'm not planning stocking4ms 12/04/14 11:51:59 AM
#1450   Anybody playing long term calls on this one? THEPK5 12/04/14 10:56:15 AM
#1449   Never can tell what IDRA's going to do. Seel 12/03/14 07:07:55 PM
#1448   Congrats to you as well. noretreat 12/03/14 05:55:25 PM
#1447   Congrats holders.. Another fine day for IDRA. :-) Citrati 12/03/14 04:13:12 PM
#1446   OT: still follow blrx? ronpopeil 12/03/14 03:54:22 PM
#1445   $IDRA Cowen Maintains Outperform On Shares Of Idera maytepper 12/03/14 03:28:34 PM
#1444   Borrowed this from a trader on another site. Citrati 12/03/14 12:16:00 PM
#1443   They are in good shape right now. As Citrati 12/03/14 11:31:51 AM
#1442   You don't think the will need funding soon? THEPK5 12/03/14 11:06:00 AM
#1441   4:34 PM ET, 12/02/2014 - Briefing.com Citrati 12/03/14 09:29:16 AM
#1440   IDRA +.29 (+8.1%) @ 3.87 on 17,098 vol MiamiGent 12/03/14 08:19:12 AM
#1439   LOOK, I don't Blame You for Profit Taking: JDUser1963 12/02/14 10:33:13 PM
#1438   Went ahead and dumped 50% of my position Randolph Duke 12/02/14 05:27:46 PM
#1437   Looks like a whale pod is feeding. Pretty Citrati 12/02/14 12:12:02 PM
#1436   On fire. Good thing I don't trade the Citrati 12/02/14 09:49:15 AM
PostSubject